NCT01117038已完成1 期
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Two-Period, Two-Cohort Crossover Study to Assess the Potential Interaction of Avanafil on the Pharmacokinetic and/or Hemodynamic Effects of Enalapril or Amlodipine in Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- VIVUS LLC
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- To measure the change in standing blood pressure after dosing
研究概览
简要总结
The purpose of this study is to determine the change in the blood pressure and pulse rate, pharmacokinetics and the safety when avanafil is taken with either enalapril or amlodipine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Voluntarily consent to participate in the study (informed consent form [ICF] must be signed and dated prior to any study related assessments).
- •Adult male subjects of 40 to 65 years of age, inclusive.
- •A body weight of at least 50 kg and a body mass index (BMI) between 18 and 32 kg/m2, inclusive [BMI will be calculated as weight in kg/(height in m)2].
- •Subjects are able to communicate with the Investigator, and to understand and comply with all requirements of study participation.
- •Medically healthy, with no clinically significant screening results (e.g., laboratory profiles, medical histories, ECGs, physical examinations, etc.), in the opinion of the Investigator.
排除标准
- •A history or presence of significant cardiovascular (including thromboembolic disorders), neurological, hematological, psychiatric, hepatic, gastrointestinal, pulmonary, endocrine, immunologic, or renal disease, or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs or place the subjects at increased risk as determined by the Investigator.
- •Any clinically significant laboratory abnormalities as judged by the Investigator.
- •A predisposition to priapism, such as subjects with sickle cell disease or blood dyscrasias.
- •Known history of cardiovascular or cerebrovascular event, or any history of angina.
- •History of fainting or vasovagal hypotension.
- •History or ECG evidence of any high-risk arrhythmia or ECG judged by the Investigator to be clinically significant.
- •Hypertrophic obstructive or other clinically significant cardiomyopathy, moderate or severe cardiac valvular disease.
- •Subjects whose pulse is lower than 50 bpm at screening.
- •Acute illness, especially any infection, within 2 weeks of dosing.
- •Supine systolic blood pressure </= 100 or >/= 140 mmHg; supine diastolic blood pressure </= 50 or >/= 95 mmHg at screening (2 rechecks are allowed).
- •Subjects with orthostatic hypotension (as evidenced by a reduction of 30 mmHg or more in systolic blood pressure, reduction of 20 mmHg or more in diastolic blood pressure, or evidence of cerebral hypoperfusion upon standing from a seated position).
- •Any history of bipolar disorder or psychosis, history of psychiatric hospitalization, greater than one lifetime episode of major depression.
- •Hemoglobin < 12.0 g/dL.
- •Positive urine drug test, positive urine alcohol test, or positive urine cotinine test at screening or at check-in on Day -
- •Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV) at screening.
- •Any history or presence of alcoholism or drug or substance abuse within 18 months or as defined by the Investigator.
- •Allergy to or previous adverse events with PDE5 inhibitors, ACE inhibitors, calcium channel blockers, or their constituents.
- •Use of any prescription or over-the-counter (OTC) medication, including herbal products, within the 14 days prior to Day 1 and throughout the study. Up to 2 g per day of acetaminophen is allowed at the discretion of the Investigator.
- •Use of any drug in Appendix 1 (drugs known to interfere with metabolism by the CYP450 3A4 enzyme) within 30 days prior to Day
- •Blood donation or significant blood loss within 56 days prior to Day
- •Plasma donation within 14 days prior to Day
- •Any use of tobacco or nicotine products within 6 months prior to Day
- •Any subject who received an investigational drug within 30 days or six half-lives, whichever is longer, prior to Day
- •Involvement in the planning and conduct of the study (applies to both VIVUS or designee staff, or staff at the investigational site).
- •Previously participated in a trial with avanafil.
- •Subjects who report having difficulty swallowing tablets, capsules, etc.
研究组 & 干预措施
enalapril and avanafil
Experimental
干预措施: avanafil and enalapril (Drug)
amlodipine and avanafil
Experimental
干预措施: avanafil and amlodipine (Drug)
结局指标
主要结局
To measure the change in standing blood pressure after dosing
时间窗: -0.5, -0.25, -0.17, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 22 hours
次要结局
- To measure the pharmacokinetic parameters of taking avanafil with enalapril(before dosing and after dosing at the hours of 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 18, 24, 36, 48)
- To measure the change in sitting and lying blood pressure and pulse rate after dosing(-0.5, -0.33, -0.17, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 22 hours)
- To determine the effects of enalapril on blood pressure and pulse rate(-0.5, -0.33, -0.17, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 22 hours)
- To measure the pharmacokinetic parameters of taking avanafil with amlodipine(before dosing and after dosing at the hours of 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 18, 24, 36, 48)
- To determine the effects of amlodipine on blood pressure and pulse rate(-0.5, -0.33, -0.17, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 22 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure MonitoringFibromyalgiaNCT00618956Forest Laboratories321
已完成
1 期
A Phase 1 Crossover Study of Blood Pressure and Heart Rate ResponseHealthy SubjectsNCT01577459Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18
已完成
1 期
Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 DaysHealthy VolunteersNCT01786915Stealth BioTherapeutics Inc.30
已完成
1 期
A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)HealthyNCT01754818Stealth BioTherapeutics Inc.30
已完成
3 期
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)HypertensionNCT00092209Organon and Co840